Overall, the landscape emerging from the literature strongly indicates that either due to genetic variants of regulatory elements or to still unidentified trans-acting factors, the expression level of Foxe1 is the likely determinant underlying different susceptibility to PTC and/or different cancer phenotypes. The gene discussed is FOXE1; the disease is cancer.